2026-10-19 06:34:38 UTC#478762newconfirmednews
KOD stock news
KOD stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-10-12 11:46:00 UTC#446304duplicateconfirmednews
H.C. Wainwright raises Kodiak Sciences price target to $126 from $96
2026-10-12 11:36:09 UTC#446235newconfirmednews
H.C. Wainwright maintains Buy rating on Kodiak Sciences, sets $126 price target
tradingviewimportance 0.40trust 0.60H.C. Wainwright & Co. 0Kodiak Sciences Inc. +0.40tarcocimab tedromer +0.40+1 entities
2026-10-07 11:00:00 UTC#425018newconfirmedpress release
Kodiak Sciences to present clinical data for three late-stage programs at AAO 2026
pr_newswireimportance 0.30trust 0.90Kodiak Sciences Inc. +0.10American Academy of Ophthalmology +0.10
2026-09-28 18:57:00 UTC#379667duplicateconfirmednews
Kodiak Sciences shares rally 150% following positive Phase 3 wet AMD trial results for Zenkuda and tabirafusp-ted
2026-09-28 18:30:00 UTC#379585newconfirmednews
LifeSci Capital Raises Kodiak Sciences (KOD) Price Target to $145.00 From $85.00
2026-09-28 17:48:38 UTC#379627updateconfirmednews
Kodiak Sciences Shares Surge 178% as Company Prepares for FDA Submission Following Successful Phase 3 Trials
zerodha pulseimportance 0.60trust 0.60Kodiak Sciences Inc. +0.80U.S. Food and Drug Administration +0.40
2026-09-28 17:38:00 UTC#379367newconfirmednews
UBS Raises Kodiak Sciences (KOD) Price Target to $120.00 From $80.00
2026-09-28 17:35:00 UTC#379380updateconfirmednews
Kodiak Sciences Shares Surge 170% as Zenkuda Shows 6-Month Dosing Potential vs Regeneron's Eylea, WSJ Reports
dow_jonesimportance 0.70trust 0.90Kodiak Sciences Inc. +0.90Regeneron Pharmaceuticals, Inc. -0.50Zenkuda +0.90+2 entities
2026-09-28 16:31:00 UTC#379018duplicateconfirmednews
HC Wainwright & Co. raises Kodiak Sciences (KOD) price target to $96 from $58, maintains Buy
2026-09-28 16:21:13 UTC#378936newconfirmednews
HC Wainwright maintains Buy rating on Kodiak Sciences, sets $96 price target
tradingviewimportance 0.40trust 0.60Kodiak Sciences Inc. +0.50H.C. Wainwright & Co., LLC +0.30tarcocimab tedromer +0.40+2 entities
2026-09-28 14:10:44 UTC#378216duplicateconfirmednews
Kodiak Sciences' DAYBREAK Phase 3 trial for Zenkuda and tabirafusp alfa tedromer meets primary endpoints
quartrimportance 0.30trust 0.60Kodiak Sciences Inc. +0.80Zenkuda +0.80tabirafusp alfa tedromer +0.80+2 entities
2026-09-28 12:11:25 UTC#377351updateconfirmednews
Premarket Movers: Nvidia Rises on $150B Buyback; Kodiak Sciences Jumps 66% on Phase 3 Trial Success
zerohedgeimportance 0.50trust 0.50NVIDIA Corporation +0.60Meta Platforms, Inc. -0.30Kodiak Sciences Inc. +0.80+2 entities
2026-09-28 11:31:00 UTC#377066updateconfirmednews
Kodiak Sciences Shares Jump 64% Following Positive Late-Stage Trial Results for Zenkuda and KSI-501
2026-09-28 11:27:10 UTC#377110duplicateconfirmednews
Kodiak Sciences' Zenkuda and tabirafusp-ted meet primary endpoints in DAYBREAK Phase 3 trial for wAMD
quartrimportance 0.40trust 0.70Kodiak Sciences Inc. +0.80Zenkuda +0.80tabirafusp-ted +0.70+1 entities
2026-09-25 22:22:00 UTC#371331updateconfirmednews
Kodiak Sciences shares jump 17% in after-hours trading ahead of Monday Phase 3 clinical trial results
dow_jonesimportance 0.40trust 0.80Kodiak Sciences Inc. +0.40Tarcocimab tedromer +0.30Tabirafusp alfa tedromer +0.30
2026-09-25 22:01:00 UTC#371297newconfirmedpress release
Kodiak Sciences to release DAYBREAK Phase 3 results for Zenkuda and KSI-501 on September 28, 2026
2026-09-25 12:30:00 UTC#368614newconfirmednews
Chardan Capital maintains $12.00 price target on Kodiak Sciences (KDK)
2026-09-24 11:41:00 UTC#362006newconfirmednews
Goldman Sachs sets $36.00 price target on Kodiak Sciences (KOD)
2026-09-17 10:09:39 UTC#326438newconfirmednews
H.C. Wainwright & Co. reiterates Buy rating on Kodiak Sciences, maintains $58 price target
tradingviewimportance 0.30trust 0.60H.C. Wainwright & Co. 0Kodiak Sciences Inc. +0.40tarcocimab tedromer +0.40